Overall Score

Political

No material political catalysts or policy changes are evident from the latest data.

As a micro-cap biotech, CLGN remains exposed to funding and regulatory approval risk, but no new policy-driven development was reported this month.

Economic

The company remains loss-making with negative margins and negative operating cash flow, indicating continued economic pressure.

Liquidity is still supported by a current ratio above 2.0 and cash per share of about $3.10, but the business remains highly dependent on capital preservation.

Social

No new social or demand-side developments were reported this month.

Investor sentiment remains constrained by the absence of profitable commercialization and the company’s ongoing operating losses.

Technological

R&D intensity remains high at roughly 20% of revenue, consistent with a development-stage biotech profile.

No new product, pipeline, or clinical update was reported this month.

Legal

No new litigation, compliance, or regulatory enforcement news was reported this month.

The company still faces standard biotech legal/regulatory approval risk tied to future development and commercialization.

Environmental

No material environmental developments were reported this month.

Environmental impact appears limited at this stage, with no new ESG-related catalyst in the latest data.